BiomX (NYSEMKT:PHGE) Shares Scheduled to Reverse Split on Tuesday, November 25th

BiomX Inc. (NYSEMKT:PHGE) shares are going to reverse split on Tuesday, November 25th. The 1-19 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, November 24th.

BiomX Stock Performance

NYSEMKT PHGE traded down $0.42 during mid-day trading on Monday, reaching $0.32. 53,300 shares of the stock were exchanged, compared to its average volume of 347,190. The company has a market capitalization of $8.42 million, a P/E ratio of -0.42 and a beta of 1.46. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.84 and a current ratio of 2.84. The business’s 50 day moving average is $0.51 and its 200-day moving average is $0.49. BiomX has a 1 year low of $0.34 and a 1 year high of $2.40.

Hedge Funds Weigh In On BiomX

A number of large investors have recently added to or reduced their stakes in the stock. Warberg Asset Management LLC acquired a new stake in BiomX in the 1st quarter worth about $55,000. Citadel Advisors LLC purchased a new stake in shares of BiomX during the third quarter worth approximately $85,000. ADAR1 Capital Management LLC acquired a new position in BiomX in the 1st quarter valued at $166,000. Allostery Investments LP lifted its holdings in BiomX by 46.1% in the 1st quarter. Allostery Investments LP now owns 940,629 shares of the company’s stock valued at $523,000 after purchasing an additional 296,796 shares in the last quarter. Finally, Alyeska Investment Group L.P. acquired a new stake in BiomX during the 3rd quarter worth $835,000. 40.57% of the stock is currently owned by institutional investors and hedge funds.

BiomX Company Profile

BiomX Inc, a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.